M
ultiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that is mediated by autoreactive B and T cells. The pivotal role of B cells in disease pathogenesis has been reinforced by the successful development of B-cell-depleting monoclonal antibodies that target the CD20 surface antigen on cells of B-cell lineage (1, 2) . The recently reported Phase 3 trials of ocrelizumab, a humanized monoclonal anti-CD20 antibody (3, 4) , revealed profound suppression of inflammation in patients with relapsing multiple sclerosis (RMS) and a partial reduction of disability progression in primary progressive multiple sclerosis (PPMS); these results mark a breakthrough in our understanding of disease pathogenesis and, most importantly, in improving the lives of patients with MS (2) (3) (4) . With subsequent approval of ocrelizumab for RMS and PPMS by the Food and Drug Administration in March 2017, representing the first and only agent ever approved for PPMS, and decisions by other regulatory bodies pending, we now seem to be at the dawn of a new era of B-cell immunology and therapeutics. However, these treatment successes also raise many unanswered questions about the fundamental role of B cells in RMS and its contribution to sustained inflammation in the progressive phase of the disease.
The first part of this review summarizes current knowledge of B-cell immunology and the principles underlying the use of CD20-depleting therapies. The second part explores the possible mechanisms of action of B-cell-depleting agents in MS, prospects for development of clinically useful biomarkers to monitor treatment response, and the potential role of other B-cell-targeting agents.
B CELLS IN MULTIPLE SCLEROSIS: A KEY PLAYER IN PATHOGENESIS
Historically, rodent T-cell-mediated acute experimental autoimmune encephalomyelitis (EAE) models have shaped a T-cell-centric view of human MS (5). First described more than 85 years ago, EAE remains the most commonly used and versatile model of CNS autoimmunity in general and, more specifically, for MS. However, EAE is not a single entity; depending on the strain or species of animal used, the antigen administered, and even the method of inoculation and the local microbial environment, distinct EAE phenotypes characterized by different immunopathologies, topographical patterns of involvement, and clinical courses (acute or chronic, relapsing or progressive) can result. In general, however, the pure T-cell-mediated models of EAE lack large sharply demarcated areas of demyelination that are the hallmark of MS (6) . Through the development of demyelinating disease models that more closely resemble human MS, and demonstration that this MS-like pattern of tissue damage results from a combined T-cell and humoral (e.g., antibody-mediated) pathology (5,7), the experimental basis was set for the clinical trials of anti-CD20 targeted B-cell therapeutics (1), eventually leading to the groundbreaking success of ocrelizumab (8) .
In MS, the presence of immunoglobulins (Ig) and complement deposition in the majority of acute demyelinating lesions is a well-recognized phenomenon (9, 10) . Moreover, oligoclonal bands (OCBs), which are intrathecally produced clonally expanded antibodies, have long been recognized as prognostic and diagnostic markers. OCBs are produced by CNS-infiltrating plasmablasts/plasma cells (11, 12) and are clonally related to B cells present in the brain parenchyma, meninges, CSF, and the periphery (11, (13) (14) (15) (16) (17) . Whether a subgroup of those intrathecally produced antibodies is indeed pathogenic (12) , or rather targeted against intracellular antigens as suggested by recent studies (18, 19) , remains unanswered (20) . Nevertheless, findings from human T-cell receptor (TCR) and B-cell receptor (BCR) repertoire studies provide strong evidence for antigen-driven clonal expansion occurring locally in the brain, CSF, and meninges (15, (21) (22) (23) (24) (25) . However, both experimental data and clinical observations, including the very rapid onset of efficacy with CD20-depleting therapies in RMS, indicate that the pathogenic role of B cells in MS is likely not restricted to antibody production (5, 26) .
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B cells are likely to influence MS pathology through additional effector functions including antigen presentation and roles in proinflammatory and regulatory immune responses (27, 28) . B cells represent a unique population of antigen-presenting cells (APCs), cells that can bind antigens, and then internalize, process, and express antigen fragments on Class II molecules of the major histocompatibility complex (MHC). In the context of costimulatory molecules, T cells that bear TCRs capable of recognizing the specific antigen-MHC complex that is being presented on the B-cell surface are then activated. What makes B cells unique among APCs is that they are highly specialized, primarily presenting only those antigens that bind to their clonal BCR or Ig molecule. By contrast, other APCs, such as microglia or dendritic cells, are able to present a broad range of exogenous and endogenous antigens. In a series of elegant experiments, transgenic mice that were selectively deficient in the expression of MHC class II molecules only on B cells were resistant to EAE induction, whereas the absence of secreted antibodies did not alter disease susceptibility (29) . These data provide direct evidence that some Tcell-mediated autoimmune responses to CNS antigens are absolutely dependent on B cells acting as APCs.
Moreover, B cells entering the CSF are important for recruiting other inflammatory cells and promoting their survival (30) , and aggregates of B cells are now known to persist as lymphoid follicle-like structures located in the meninges of patients with chronic MS, and especially secondary progressive (SPMS) (31, 32) . Finally, B cells from patients with MS have been reported to be inherently polarized toward secretion of high levels of proinflammatory molecules including interleukin-6 and granulocyte macrophage-colony stimulating factor (GM-CSF), and lower levels of the regulatory cytokine IL-10 (33, 34) . This could reflect an influence of genetic factors active on B cells that are involved in MS risk (35) , an environmental effect (see microbiome, below), or a combination of both.
Although the rapid response of B-cell depletion therapy on focal inflammation and RMS argues against a primary effect on antibodies, as initially hypothesized, the possible elimination of a yet-to-be-identified autoantibody in MS cannot be completely excluded. CD20 depletion ablates short-lived plasmablasts, which are a potentially important effector cell subset in MS (36) . Also, antibodies of the IgG4 subclass, which are often synthesized by short-lived plasmablasts, show a rapid decline in patients with IgG4-mediated autoimmune disease, which is paralleled by a clinical response (37) . The response in RMS could also reflect the rapid depletion of peripheral autoreactive B cells, as functional studies in MS have shown that B-cell tolerance is impaired in the periphery, while central tolerance is normal in MS (38) , unlike the case in many other autoimmune diseases where central tolerance is impaired (39) .
CD20 + DEPLETION: TARGETING THE B-CELL LINEAGE AND DISTINCT T-CELL SUBSETS
Ocrelizumab is a humanized monoclonal antibody of the IgG1 subtype that targets the large extracellular loop of CD20 (3, 40) , a surface protein that functions as an ion channel. Full humanization and the distinct epitope on CD20 differentiate it from the other CD20-depleting agents, rituximab and ofatumumab. CD20 is expressed on B cells across different stages of maturation, ranging from pre-B cells in the bone marrow to short-lived plasmablasts. It spares long-lived CD20-negative plasma cells, which produce antibodies directed against previously encountered pathogens and vaccines, which might explain the favorable safety profile. The B-cell-depleting effect of ocrelizumab is mediated through apoptosis, antibodydependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). Its stronger ADCC than CDC capacity differentiates ocrelizumab from other CD20-targeting agents (rituximab and ofatumumab). Rituximab, a chimeric human-mouse anti-CD20 antibody, was the first B-cell-depleting agent used for MS in preliminary clinical trials (1) and is the forerunner to ocrelizumab, whereas ofatumumab, a fully human anti-CD20 antibody that targets a different epitope of CD20, also showed promising efficacy against RMS in a preliminary trial (41) , and a pivotal Phase III study is in progress.
Treatment with ocrelizumab is administered initially as 2 paired doses of 300 mg i.v. separated by a 2-week interval, and cycles are repeated as single infusions of 600 mg i.v. every 6 months. A single treatment leads to a rapid depletion of CD20 + B cells. Circulating B cells, which only represent approximately 2% of the total B-cell pool, are the compartment most efficiently depleted by CD20-targeting agents. In contrast, the B-cell depletion in lymphoid organs and other tissues including the CNS is limited (42) . Rituximab has been found to eliminate B cells in the CSF and in CNS perivascular spaces without any detectable effect on OCBs (43) (44) (45) . This is most likely explained by the highly effective and sustained depletion of circulating B cells, which prevent their recirculation into the target tissue, but persistence of some B cells residing in protected CNS niches. Four to 8 months after treatment, B cells repopulate in the peripheral blood from progenitors residing in the bone marrow. Repopulating B cells in the peripheral blood are comprised of primarily naive and immature B cells, with fewer memory B cells and plasmablasts (1, 16, 46, 47) . Potentially disease-driving memory B cells and proinflammatory B cells seem to show a prolonged suppression up to 2 years after a single course of B-cell depletion (33, 46) . Because of its sparing of antibody-producing plasma cells, and the long half-life of plasma cells, CD20-targeting agents typically do not cause a marked reduction in serum IgG, although modest reductions in IgA and IgM levels can occur (1).
However, with long-term use of ocrelizumab, antibody levels will most likely decrease, requiring ongoing monitoring of antibody levels.
Although classically recognized as a protein expressed by B cells, CD20 + B-cell depletion also leads to depletion of a small population of T cells and significant alteration of T-cell function. This effect is mediated through direct depletion of a small subset of T cells and also through the loss of B-cell influenced effects on T cells. Surprisingly, it is now recognized that expression of CD20 is not restricted to B cells, but is also expressed on w5% of CD3 + T cells, albeit at lower levels (CD20 dim ) (46, 48) . In MS, and in other neurologic diseases, CD3 + CD20 dim T cells are present at similar frequencies in cerebrospinal fluid (CSF) and peripheral blood (48) with a possible small increase in MS (46) . Phenotypically CD3 + CD20 dim cells are more prevalent among CD8 + than CD4 + T cells (46, 48) . Functionally, they show a higher frequency of proinflammatory cytokine production (INFg, TNFa, IL-17) (48). CD3 + CD20 dim T cells are effectively depleted by CD20-targeting therapy but repopulate earlier than CD20 + B cells (46, 48) . Of note, CD3 + CD20 dim T-cell replenishment has been tentatively associated with clinical relapse (48) .
In addition to direct effects on CD3 + CD20 dim T cells, limited data indicate that a reduction in proliferation and proinflammatory cytokine production of other T-cell subsets also occurs after B-cell depletion (49) . In systemic lupus erythematosus, CD3 + CD25 + FoxP3 + regulatory T cells increase after CD20 depletion (50) . The effects of CD20 depletion on T cells are only beginning to be defined, and additional work is sorely needed to define the biological relevance of CD20 + T cells and perturbations in other Tcell populations accompanying anti-CD20 therapy. A better understanding of the functional consequences of B-cell depletion therapy on T cells could illuminate the mechanism of action of these drugs on MS and could possibly also lead to development of biomarkers for monitoring anti-CD20 therapy.
OUTSTANDING RESEARCH QUESTIONS AND NOVEL AVENUES FOR B-CELL-DEPLETING THERAPIES
Although the selective depletion of CD20 + B cells as monotherapy in MS suppresses disease activity in both RMS and PPMS, the success of this highly selective immune therapy also raises many new questions about the role of B cells in MS and the underlying pathophysiology of PPMS.
Central Nervous System Effects of Ocrelizumab
The beneficial effects of ocrelizumab on clinical and MRI indices of progression in PPMS have highlighted the role of B cells in progressive forms of the disease, previously considered to be primarily driven by neurodegeneration. As noted above, there is limited evidence that OCBs can persist in the CSF even after chronic treatment with CD20-depleting therapy, which indicates that there is an ongoing humoral immune response within the CNS that is resistant to treatment. In light of evidence for sequestration of some pathogenic immune responses behind an intact blood-brain barrier (BBB), particularly in chronic MS, intrathecal administration of ocrelizumab might improve therapeutic deletion of the relevant B-cell subsets. A recent preliminary trial of intrathecal CD20-B-cell depletion with rituximab in SPMS, however, showed no clinical benefit, possibly because insufficient concentrations of rituximab were present in the CSF and perhaps also due to inadequate CDC capacity in the CNS compared with the periphery (51). It is possible that ocrelizumab, which relies on ADCC more than CDC in its mechanism of action, might be more potent than rituximab in mediating CNS B-cell depletion through an intrathecal route.
From a practical perspective, intrathecal dosing is not an attractive option for chronic use. More promising are approaches that use small-molecule drugs that cross the BBB effectively or designer antibodies that can shuttle across the BBB by exploiting endogenous receptor-mediated transporters (52) . Recent data from Alzheimer trials used bispecific antibodies, in which one half of the antibody is designed to exploit an existing transportation system (the transferrin receptor) while the other half targets the protein of interest (amyloid plaque); this approach has shown promise in overcoming the BBB for therapeutic antibody delivery (53) . Further studies need to address current safety concerns associated with bispecific antibodies (54) and development of more efficient technologies for enhanced shuttling of therapeutic antibodies across the BBB.
Targeted Depletion of Selective Pathogenic CD20 + B-Cell Subsets
Ocrelizumab leads to highly efficient B-cell depletion and demonstrates a favorable safety profile (3, 4, 8) . Infusion reactions and infections are the most frequent adverse effects reported with CD20 depletion, and with ocrelizumab, the induction of antidrug antibodies is very low (0.4%) because of its low immunogenicity (3). Very recently, one case of progressive multifocal leukoencephalopathy (PML) was reported in a John Cunningham virus-positive patient who had recently begun treatment with ocrelizumab; the PML was likely unrelated to ocrelizumab but due to previous treatment with natalizumab, an immunomodulatory agent well known to be associated with PML risk. However, continued vigilance will be important because many patients are expected to begin treatment with ocrelizumab in the near future. In the clinical trials, there was also an imbalance in the number of malignancies, and especially in cases of female breast cancer, present with ocrelizumab compared with interferon (IFN)-b1 or placebo use (3, 4) . Although additional analyses and longer-term follow-up during the extension phase of the studies provide some optimism that these statistical imbalances may not represent a true biologic increase in risk, further long-term assessment of the safety profile of ocrelizumab will be required to fully define the risk of these rare adverse events.
Despite this overall favorable safety profile, an even more targeted treatment of a selective pathogenic CD20 + B-cell subset in the future would be desirable. Although GM-CSF-producing B cells have been identified more recently as a proinflammatory subset that might be potentially pathogenic in patients with MS (33), and B cells from patients with MS are reported to secrete yet unidentified factors toxic to oligodendrocytes (55) and neurons (56) , functional studies are needed to confidently identify disease-driving Bcell subsets and antigen-specific pathogenic cells.
B-Cell-Related Biomarkers to Tailor Ocrelizumab Treatment to the Individual Needs of Every Patient
In Phase III clinical trials, ocrelizumab was administered at fixed intervals of 24 weeks independent of an individual's Bcell reconstitution kinetics. In the real-life clinical setting, the optimal treatment cycle and duration of treatment still needs to be defined. B-cell reconstitution, as determined by CD19 + B-cell levels in the peripheral blood, is currently the only readily available specific biomarker of treatment, but based on studies in rheumatoid arthritis, it is clear that Bcell levels should not be used as a guide to the need for   FIG. 1 . Neurotropic view of B-cell trafficking and function in autoimmunity. Multifunctional B cells evolve through a series of differentiation stages, from stem cells to antibody-producing plasma cells. B cells are potent antigen-presenting cells; participate in antigen transport; produce a range of pro-inflammatory and regulatory cytokines; and secrete antibodies that have undergone affinity maturation in germinal centers of lymphoid structures. In addition to these roles in adaptive immunity, B cells are also important players in innate immunity primarily through signaling via TLRs, a family of receptors that can recognize DAMPs and PAMPs. In chronic MS, memory B cells and plasma cells also accumulate in protected follicle-like structures located in the meninges and perivascular spaces. All of these functions of B cells may contribute to the effects of B-cell depletion on disease activity in MS. As shown, B cell-depleting therapies targeted against CD20 and CD19 eliminate distinct B cell subpopulations. B, B cell; APC, antigen presenting cell; BCR, B-cell receptor; CSF, cerebrospinal fluid; DAMPs, damage-associated molecular pattern molecules; GM-CSF, granulocyte macrophage-colony stimulating factor; IL, interleukin; LT-a, lymphotoxin-alpha; MHC, major histocompatibility complex; P, plasma cell; M, microglia/monocytes; PAMPs, pathogen-associated molecular pattern molecules; T, T cell; TCR, T-cell receptor; TLR, toll-like receptor; TNF-a, tumor necrosis factor alpha.
retreatment. Among potential future biomarkers, circulating memory B cells, B-cell cytokine profiles, shed receptors of activated B cells and plasma cells (such as the B-cell maturation antigen [57] and the transmembrane activator and calcium-modulator and cyclophilin ligand interactor [58] ), CD3 + CD20 dim T-cell levels, and neurofilament light levels as a marker for neurodegeneration are all under study. A recently launched, open-label, multicenter biomarker study (OBOE) of patients with RMS and PPMS will address some of the issues through collection and immunological assessment of peripheral and CSF B and T cells before and during ocrelizumab treatment.
Effects of B-Cell Depletion on the Mucosal BCell Compartment
A novel and rapidly evolving field of interest is the composition of the gut microbiome as a potential diseaserelevant environmental factor and its impact on adaptive and innate immunity in the context of autoimmunity. Recent evidence from animal models and human MS suggest that the triggers and perpetuating factors of MS might be traced to the gut (59) (60) (61) . Because the differential composition of the gut microbiota in patients with MS compared with controls is only beginning to be unraveled, the modifying effect of CD20-depleting therapies on the microbiome and the role of B cells and antibodies in the immunologic and neurohumoral communication between the gut and the brain-the so-called "gut-brain axis"-in MS remain elusive (62) (63) (64) .
At the microbiota-mucosal interface in the gut, B cells are important cellular and humoral mediators of immunity. Gut microbiota and microbial products have been shown to directly regulate B-cell development, activation, and differentiation (65) (66) (67) (68) . In a complementary fashion, the humoral B-cell responses mediate homeostasis of the microbial composition through production of antibodies, in particular IgA. IgA binding of gut bacteria has recently been shown to identify potential proinflammatory bacteria in the context of autoimmunity (69) (70) (71) and, thus, might function as an important regulator between mucosal and systemic immunity. Although IgA is the most abundantly produced immunoglobulin in humans, its role in the pathogenesis of MS has been understudied. Interestingly, mucosal IgA plasma cells residing in the gut lamina propria are not depleted by anti-CD20-depleting therapy (72) . In light of clinical trials with CD19-depleting therapies (Inebilizumab, MEDI-551) (73) that additionally target the pro-B-cell and plasma cell compartment, the relevance of IgA plasma cells in the gut and the consequences of potential depletion by tissue-resident B cells in the gut for mucosal homeostasis need to be addressed.
Novel Therapeutic Strategies for B-Cell-Depletion
As noted above, anti-CD20 therapies eliminate most circulating B cells, leaving B cells in secondary lymphoid organs and other sites, such as meningeal follicle-like structures, unaffected. The resistance of B-cell niches to treatment with anti-CD20 therapies likely explains the only partial effect of CD20-depleting agents on PPMS and the appearance of SPMS during CD20 depletion (43) . Promising alternate areas of targeting those nicheresiding B cells are the development of monoclonal antibodies that target plasma cells and small molecules that inhibit critical B-cell signaling pathways.
MEDI-551 (Inebilizumab), a humanized, monoclonal antibody, binds with high affinity to CD19, a surface marker expressed on a broad range of B cells including long-lived plasma cells (73) . It is currently being evaluated in a Phase II clinical trial in patients with neuromyelitis optica spectrum disease. Another possible target antigen for monoclonal antibody therapy is CD38, a surface protein expressed on plasma cells. Daratumumab, an anti-CD38 monoclonal antibody, is approved for treatment of multiple myeloma (74) . However, the wide expression of CD38 on other immune cells, including regulatory B cells, could discourage its potential use in MS.
Targeting selective pathways downstream of the BCR signaling with small molecules is another promising strategy. BCR signaling activates phosphoinositide 3-kinase (P13K), a lipid kinase, to produce a second messenger molecule, which recruits other proteins to the membrane. Novel BCR signaling pathway inhibitors include Ibrutinib and Idelalisib among others (75) (76) (77) . Both molecules target the P13K pathway and inhibit downstream BCR signaling, thus interfering with B-cell activation. Further studies will need to assess their capability to cross the BBB.
CONCLUSIONS
It seems likely that ocrelizumab will emerge as a vital treatment of RMS and PPMS. Equally important, the remarkable clinical success of CD20-depleting therapies has also fundamentally reshaped our understanding of MS pathogenesis. Initially developed based on experimental data derived from an improved disease model and a goal to eliminate pathogenic antibodies, the profound antiinflammatory effect of anti-CD20 therapy has stimulated new efforts to elucidate previously unappreciated functional roles of B cells in this complex demyelinating disease. Although many questions remain, it is clear that novel insights into the fundamental cause of MS are likely to be revealed and that a new era of B-cell-directed approaches to this disease will emerge (Fig. 1) .
